Simulating α/β selectivity at the human thyroid hormone receptor: Consensus scoring using multidimensional QSAR

ChemMedChem

Volumn 2, Issue 1, 2007, Pages 78-87

  Vedani, Angelo ^a   Zumstein, Martin ^a   Lill, Markus A ^a   Ernst, Beat ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Consensus scoring; Flexible docking; Multidimensional QSAR; Structure activity relationships; Thyroid receptor

Indexed keywords

THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA;

ARTICLE; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; COMPUTER PROGRAM; COMPUTER SIMULATION; CONFORMATION; HUMAN; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA;

EID: 34249931009     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600212     Document Type: Article

References (46)

1. M. A. Lazar, Endocr. Rev. 1993, 14, 184-193.
2. a) R. J. Kavlock, G. P. Daston, C. DeRosa, P. Fenner-Crisp, L. E. Gray, S. Kaattari, G. Lucier, M. Luster, M. J. Mac, Z. Maczka, R. Miller, J. Moore, R. Rolland, G. Scott, D. M. Sheehan, T. Sinks, H. A. Tilson, Environ. Health Perspect. 1996, 104 (Suppl. 4), 715-740;
3. b) T. Colborn, F. S. von Saal, A. M. Soto, Environ. Health Perspect. 1993, 101, 378- 384;
4. c) E. Carlsen, A. Giwercman, N. Keiding, N. E. Skakkebaek, Br. Med. J. 1992, 305, 609-613.
5. L. Ye, Y. L. Li, K. Mellstrøm, C. Mellin, L.-G. Bladh, K. F. Koehler, N. Garg, A. M. Garcia Collazom, C. Litten, B. Husman, K. Persson, J. Ljunggren, G. Grover, P. G. Sleph, R. George, J. J. Malm, J. Med. Chem. 2003, 46, 1580-1588.
6. A. Hedfors, T. Appleqvist, B. Carlsson, L.-G. Bladh, C. Litten, P. Agback, M. Grynfarb, K. F. Koehler, J. J. Malm, J. Med. Chem. 2005, 48, 3114-3117.
7. a) A. Vedani, M. Dobler, M. A. Lill, Pharmacol. Toxicol. 2006, 99, 195-208;
8. b) A. Vedani, M. Dobler, M. A. Lill, Toxicol. Appl. Pharmacol. 2005, 207, 398-407;
9. c) A. Vedani, M. Dobler, M. A. Lill, Altex Chromatogram 2005, 22, 123-134.
10. http://www.biograf.ch/index.php?id=projects.
11. C. Hansch, T. Fujita, J. Am. Chem. Soc. 1964, 86, 1616-1626.
12. R. D. Cramer, M. Milne, Abstracts of papers of the Am. Chem. Soc., Meeting, April 1979, COMP 44.
13. a) R. D. Cramer, D. E. Patterson, J. D. Bunce, J. Am. Chem. Soc. 1988, 110, 5959-5967;
14. b) 3D-QSAR in drug design. Theory, methods and applications (Ed.: H. Kubinyi), ESCOM Science Publishers B.V., Leiden, 1993;
15. c) H. Kubinyi, Drug Discovery Today 1997, 2, 457-467;
16. d) H. Kubinyi, Drug Discovery Today 1997, 2, 538-546;
17. e) H. Kubinyi, G. Folkers, Y. C. Martin, Perspect. Drug Discovery Des. 1998, 12, 3-23.
18. a) A. J. Hopfinger, S. Wang, J. S. Tokarski, B. Q. Jin, M. Albuquerque, P. J. Madhav, C. Duraiswami, J. Am. Chem. Soc. 1997, 119, 10509-10524;
19. b) S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, S. A. Wrighton, J. Pharmacol. Exp. Ther. 1999, 290, 429-438;
20. c) A. Vedani, D. R. McMasters, M. Dobler, Quant. Struct.-Act. Relat. 2000, 19, 149-161;
21. d) A. Vedani, H. Briem, M. Dobler, K. Dollinger, D. R. McMasters, J. Med. Chem. 2000, 43, 4416-4427.
22. http://www.rcsb.org/pdb.
23. A. Vedani, M. Dobler, P. Zbinden, J. Am. Chem. Soc. 1998, 120, 4471-4477.
24. a) A. Vedani, M. Dobler, J. Med. Chem. 2002, 45, 2139-2149;
25. b) A. Vedani, H. Dollinger, K.-M. Hasselbach, M. Dobler, M. A. Lill, J. Med. Chem. 2005, 48, 1515-1527;
26. c) M. A. Lill, F. Winiger, A. Vedani, B. Ernst, J. Med. Chem. 2005, 48, 5666-5674;
27. d) M. A. Lill, M. Dobler, A. Vedani, ChemMedChem 2006, 1, 73-81.
28. A. Vedani, M. Dobler, M. A. Lill, J. Med. Chem. 2005, 48, 3700-3703.
29. a) A. Vedani, D. W. Huhta, J. Am. Chem. Soc. 1990, 112, 4759-4767;
30. b) A. Vedani, D. W. Huhta, J. Am. Chem. Soc. 1991, 113, 5860-5862;
31. c) http://www.biograf.ch/downloads/yeti.pdf.
32. http://www.biograf.ch/downloads/quasar.pdf.
33. M. A. Lill, A. Vedani, M. Dobler, J. Med. Chem. 2004, 47, 6174-6186.
34. http://www.biograf.ch/downloads/raptor.pdf.
35. M. A. Lill, M. Dobler, A. Vedani, J. Chem. Inf. Model., 2006, 46, 2135-2145.
36. F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, W. C. Still, J. Comput. Chem. 1990, 11, 440-467.
37. S. J. Weiner, P. A. Kollmann, D. A. Case, U. C. Singh, C. Ghio, G. Alagona, S. Profeta, Jr., P. Weiner, J. Am. Chem. Soc. 1984, 106, 765-784.
38. C. J. Cramer, D. G. Truhlar, J. Comput.-Aided Mol. Des. 1992, 6, 629-666.
39. a) J. J. Hangeland, A. M. Doweyko, T. Dejneka, T. J. Friends, P. Devastale, K. Mellstrøm, J. Sandberg, M. Grynfarb, J. S. Sack, H. Einspahr, M. Färnegårdh, B. Husman, J. Ljunggren, K. F. Koehler, C. Sheppard, J. Malm, D. E. Ryono, Bioorg. Med. Chem. Lett. 2004, 14, 3549-3553;
40. b) R. L. Dow, S. R. Schneider, E. S. Paight, R. F. Hank, P. Chiang, P. Cornelius, E. Lee, W. P. Newsome, A. G. Swick, J. Spitzer, D. M. Hargrove, T. A. Patterson, J. Pandit, B. A. Chrunyk, P. K. LeMotte, D. E. Danley, M. H. Rosner, M. J. Ammirati, S. P. Simons, G. K. Schulte, F. Tate, P. DaSilva-Jardinea, Bioorg. Med. Chem. Lett. 2003, 13, 379-382.
41. a) H. C. Cheng, J. Pharmacol. Toxicol. Methods 2001, 46, 61-71;
42. b) M. Zumstein, MSc Thesis, Universityof Basel, Switzerland, 2005.
43. P. Zbinden, M. Dobler, G. Folkers, A. Vedani, Quant. Struct.-Act. Relat. 1998, 17, 122-130.
44. Relative to the lowest-energybinding mode of each compound.
45. For the thyroid receptor β, those amino acid residues correspond to Arg 282, Arg 316, Phe269, Phe272, Met442, and Phe 445, respectively.
46. In principle, these simulations should be run with all six available induced-fit scenarios (field-minimized, linear, or based on the steric, electrostatic, hydrogen-bond or lipophilic potential). For fairness, we used the induced-fit scenario based on the lipophilic potential, which emerged from the simulation at the 6D-QSAR level.